Docetaxel pharmacogenetics and its influence on the pharmacokinetics pharmacodynamics of docetaxel in asian nasopharyngeal cancer patients

DOCETAXEL PHARMACOGENETICS AND ITS INFLUENCE ON THE PHARMACOKINETICS / PHARMACODYNAMICS OF DOCETAXEL IN ASIAN NASOPHARYNGEAL CANCER PATIENTS Chew Sin Chi B. Health Sciences (Hons), University of Adelaide A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY DEPARTMENT OF PHARMACOLOGY NATIONAL UNIVERSITY OF SINGAPORE 2013 DECLARATION I hereby declare that this thesis is my original work and it has been written by me in its entirety. I have duly acknowledged all the sources of information which have been used in the thesis. This thesis has also not been submitted for any degree in any university previously. ---------------------Chew Sin Chi (21 November 2013) i ACKNOWLEDGEMENTS First and foremost, I would like to thank my supervisor, Professor Balram Chowbay for his support, guidance and invaluable insights throughout my postgraduate studies. Four-year stint under his guidance has helped me to mature as a student and a researcher. I would also like to express my gratitude to Professor Edmund Lee for his constructive and insightful comments during project discussions. I was very fortunate to be acquainted with another PhD candidate, Joanne Lim Siok Liu, who has shared weal and woe with me throughout the training process. Completing this work would have been more difficult were it not for the support and friendship that she offered. I am also grateful to the colleagues in Clinical Pharmacology Laboratory, National Cancer Centre Singapore who have provided technical support in my work. I am thankful to Dr Tan Eng Huat and Dr Darren Lim Wan Teck from the Department of Medical Oncology for providing the clinical samples for this study, as well as the patients who were involved in this study. For the financial support, I would like to thank National Medical Research Council Singapore for study grants (NMRCB1011 and NMCCG10122) and National University of Singapore for the research scholarship. Last but not least, I would like to express my deepest thanks to my family and people who are close to me for their unwavering support and encouragement. Their presence has provided me the strength to persevere through the difficult times. ii TABLE OF CONTENTS CONTENTS SUMMARY PUBLICATIONS AND ABSTRACTS LIST OF TABLES LIST OF FIGURES LIST OF ABBREVIATIONS 1.INTRODUCTION 1.1.Regulatory nuclear receptors 1.1.1.Pregnane X receptor (PXR) 1.1.1.1.Pharmacogenetics of PXR 1.1.2.Constitutive androstane receptor (CAR) 1.1.2.1.Pharmacogenetics of CAR 1.1.3.Retinoid X receptor alpha (RXRα) 1.1.3.1.Pharmacogenetics of RXRα 1.1.4.Hepatocyte nuclear factor 4-alpha (HNF4α) 1.1.4.1.Pharmacogenetics of HNF4α 1.2.Drug metabolising enzymes 1.2.1.Phase I biotransformation reactions 1.2.1.1.Pharmacogenetics of cytochrome (CYP) P450 enzymes 1.2.1.1.1.Cytochrome P450, family 3, subfamily A, polypeptide (CYP3A4) 1.2.1.1.2.Cytochrome P450, family 3, subfamily A, polypeptide (CYP3A5) 1.2.2.Phase II biotransformation reactions 1.2.2.1.Pharmacogenetics of phase II drug metabolising enzymes 1.2.2.1.1.Uridine diphosphate glucuronyltransferase family, polypeptide A1 (UGT1A1) 1.3.Drug transporters 1.3.1.Influx transporters 1.3.1.1.Solute carrier (SLC) superfamily 1.3.1.2.Role of hepatic organic anion transporter polypeptide member 1B1 (OATP1B1) and 1B3 (OATP1B3) in drug disposition 1.3.1.3.Pharmacogenetics of influx transporters PAGE ix xii xiv xviii xx 12 15 18 20 23 25 28 28 32 32 35 38 39 39 42 42 43 44 45 iii CONTENTS 1.3.1.3.1.Solute carrier organic anion transporter family, member 1B1 (SLCO1B3) 1.3.2.Efflux transporters 1.3.2.1.ATP binding cassette (ABC) superfamily 1.3.2.2.Role of ABC transporter proteins in drug disposition and chemoresistance 1.3.2.2.1.ATP-binding cassette, subfamily B, member (ABCB1) 1.3.2.2.2.ATP-binding cassette, subfamily C, member (ABCC2) 1.3.2.2.3.ATP-binding cassette, subfamily G, member (ABCG2) 1.3.2.3.Pharmacogenetics of drug efflux transporters 1.3.2.3.1.ATP-binding cassette, subfamily B, member (ABCB1) 1.3.2.3.2.ATP-binding cassette, subfamily C, member (ABCC2) 1.3.2.3.3.ATP-binding cassette, subfamily G, member (ABCG2) 1.4.Clinical pharmacology of docetaxel 1.4.1.Introduction 1.4.2.Physicochemical properties of docetaxel 1.4.3.Mechanism of action 1.4.4.Pharmacokinetics 1.4.4.1.Administration and distribution 1.4.4.2.Metabolism 1.4.4.3.Excretion 1.4.4.4.Factors affecting pharmacokinetics 1.4.5.Pharmacodynamics 1.5.Nasopharyngeal cancer and docetaxel treatment 1.5.1.Incidence and trends 1.5.2.Nasopharyngeal cancer chemotherapy and regimens 1.5.3.Taxane-based chemotherapy in metastatic nasopharyngeal cancer 1.6.Knowledge gaps in docetaxel pharmacogenetics 1.6.1.Study hypothesis 1.6.2.Objectives 2.MATERIALS AND METHODS 2.1.Study design 2.2.Study population PAGE 45 47 48 52 52 53 54 56 56 57 59 61 61 61 63 66 66 67 69 71 73 79 79 79 81 83 85 86 88 88 89 iv CONTENTS 2.2.1.Healthy subjects 2.2.2.Nasopharyngeal cancer patients 2.2.2.1.Inclusion criteria 2.2.2.2.Exclusion criteria 2.2.2.3.Screening evaluations 2.2.2.4.Docetaxel administration, dosing schedule and concomitant therapy 2.3.Chemicals, reagents and equipments 2.4.Pharmacogenetics analysis 2.4.1.DNA extraction from whole blood 2.4.2.Gene screening and SNP selection 2.4.3.Amplification of target genes by polymerase chain reactions (PCR) and primer design 2.4.4.Purification 2.4.5.DNA sequencing 2.4.5.1.Cycle sequencing 2.4.5.2.Ethanol precipitation 2.4.6.SNP detection, genotyping and labelling 2.4.7.Pharmacogenetics of regulatory nuclear receptors 2.4.7.1.Pregnane X receptor (PXR) 2.4.7.2.Constitutive androstane receptor (CAR) 2.4.7.3.Retinoid X receptor (RXRα) 2.4.7.4.Hepatocyte nuclear factor 4-alpha (HNF4α) 2.4.8.Pharmacogenetics of metabolism enzymes 2.4.8.1.Cytochrome P450 3A4 (CYP3A4) 2.4.8.2.Cytochrome P450 3A5 (CYP3A5) 2.4.9.Pharmacogenetics of influx transporters 2.4.9.1.Solute carrier organic anion transporter, family member 1B3 (SLCO1B3) 2.4.10.Pharmacogenetics of efflux transporters 2.4.10.1.ATP Binding Cassette, subfamily B, member (ABCB1) 2.4.10.2.ATP Binding Cassette, subfamily C, member (ABCC2) 2.4.10.3.ATP Binding Cassette, subfamily G, member (ABCG2) 2.5.Pharmacokinetics and pharmacodynamics of docetaxel 2.5.1.Pharmacokinetics 2.5.1.1.High performance liquid chromatography (HPLC) assay PAGE 89 89 90 91 92 94 95 96 96 98 101 104 104 104 105 106 107 107 109 111 116 118 118 118 119 119 121 121 122 122 123 123 123 v CONTENTS 2.5.1.1.1.Instrumentation and chromatographic conditions 2.5.1.1.2.Standard stock solutions, calibration and quality control samples 2.5.1.1.3.Sample preparation and analysis 2.5.1.1.4.Estimation of pharmacokinetic parameters 2.5.2.Pharmacodynamics 2.5.2.1.Hematological toxicity 2.5.2.2.Non-hematological toxicity 2.6.Statistical analysis 2.6.1.Pharmacogenetic analysis 2.6.2.In-silico analysis of SNPs 2.6.3.Pharmacokinetic / pharmacodynamicpharmacogenetic correlations 3.RESULTS AND DISCUSSIONS 3.1.Patient demographic and clinical characteristics (N = 50) 3.2.Pharmacokinetics of docetaxel 3.3.Pharmacodynamics of docetaxel 3.4.Pharmacokinetic / pharmacodynamic-pharmacogenetic correlations of regulatory nuclear receptors 3.4.1.Pregnane X receptor (PXR) 3.4.1.1.PXR Pharmacogenetics in healthy populations 3.4.1.1.1.In-silico prediction of SNP effects 3.4.1.2.Pharmacokinetic / pharmacodynamic-pharmacogenetic correlations 3.4.1.3.Discussion 3.4.2.Constitutive androstane receptor (CAR) 3.4.2.1.CAR pharmacogenetics in healthy populations 3.4.2.1.1.In-silico prediction of SNP effects 3.4.2.1.2.Linkage and tag-SNPs derivation 3.4.2.2.Pharmacokinetic / pharmacodynamic-pharmacogenetic correlations 3.4.2.2.1.Single SNP association PAGE 123 124 124 125 127 127 127 128 128 128 129 131 131 133 141 148 148 148 149 151 158 162 162 169 169 176 176 vi CONTENTS 3.4.2.3.Discussion 3.4.3.Retinoid X receptor-alpha (RXRα) 3.4.3.1.RXRα pharmacogenetics in healthy populations 3.4.3.1.1.In-silico prediction of SNP effects 3.4.3.1.2.Linkage and tag-SNPs derivation 3.4.3.2.Pharmacokinetic / pharmacodynamic-pharmacogenetic correlations 3.4.3.2.1.Single SNP association 3.4.3.2.2.Haplotype association 3.4.3.2.2.1.Haplotype derivations in patients 3.4.3.2.2.2.Haplotype associations with docetaxel pharmacokinetics 3.4.3.3.Discussion 3.4.4.Hepatocyte nuclear factor alpha (HNF4α) 3.4.4.1.HNF4α pharmacogenetics in healthy populations 3.4.4.1.1.In-silico prediction of SNP effects 3.4.4.1.2.Linkage and tag-SNPs derivation 3.4.4.2.Pharmacokinetic / pharmacodynamic-pharmacogenetic correlations 3.4.4.2.1.Single SNP association 3.4.4.2.2.Haplotype association 3.4.4.2.2.1.Haplotype derivations in patients 3.4.4.2.2.2.Haplotype associations with docetaxel pharmacokinetics 3.4.4.3.Discussion 3.5.Pharmacokinetic / pharmacodynamic-pharmacogenetic correlations of drug metabolism enzymes 3.5.1.Cytochrome 3A4/5 3.5.1.1.CYP3A4/5 pharmacogenetics in healthy and patient populations 3.5.1.2.Pharmacokinetic / pharmacodynamic-pharmacogenetic correlations 3.5.1.3.Discussion 3.6.Pharmacokinetic / pharmacodynamic-pharmacogenetic correlations of drug influx transporter PAGE 183 186 186 187 205 209 209 220 220 223 226 229 229 242 247 251 251 266 266 269 271 276 276 276 277 277 282 vii CONTENTS 3.6.1.Solute carrier organic anion transporter family, member 1B3 (SLCO1B3) 3.6.1.1.SLCO1B3 pharmacogenetics in healthy populations 3.6.1.1.1.Linkage and haplotypetagging SNPs (htSNPs) derivation 3.6.1.1.2.In-silico prediction of SNP effects 3.6.1.2.Pharmacokinetic / pharmacodynamic-pharmacogenetic correlations 3.6.1.2.1.Single SNP association 3.6.1.2.2.Haplotype association 3.6.1.3.Discussion 3.7.Pharmacokinetic / pharmacodynamic-pharmacogenetic correlations of drug efflux transporter 3.7.1.ATP-binding cassette, B1, C2 and G2 (ABCB1, ABCC2 and ABCG2) 3.7.1.1.ABCB1, ABCC2 and ABCG2 pharmacogenetics in healthy and patient populations 3.7.1.2.Pharmacokinetic / pharmacodynamic-pharmacogenetic correlations 3.7.1.3.Discussion 3.8.Pharmacokinetic of the outliers 3.8.1.Detection of pharmacokinetic outliers 3.8.2.Demographic and baseline clinical characteristics of pharmacokinetic outliers 3.8.3.Pharmacodynamics of pharmacokinetic outliers 3.8.4.Investigation of the genetic basis of pharmacokinetic outliers 3.8.5.Discussion 4.CONCLUSIONS AND FUTURE DIRECTIONS BIBLIOGRAPHY APPENDICES PAGE 282 282 296 297 308 308 319 324 328 328 328 333 340 345 345 347 348 349 352 354 361 viii SUMMARY This is a study aimed at elucidating the genetic basis of inherited differences in docetaxel pharmacokinetics and pharmacodynamic in local Chinese nasopharyngeal cancer patients (N = 50). The following genes involved in the biochemical pathways of docetaxel were studied: regulatory nuclear receptors (PXR, CAR, RXRα, HNF4α), drug metabolism enzymes (CYP3A4, CYP3A5) and drug transporters (ABCB1, ABCC2, ABCG2, SLCO1B3). The docetaxel pharmacokinetic profile of the patients was characterised by high degree of interindividual variability, with approximately 4- to 6-fold variations observed in Cmax, AUC0-∞ and CL. Grade 3/4 haematological and non-haematological toxicity events across all cycles occurred in 30% of the patients (N = 15). An exposure-toxicity relationship was observed, in which patients with grade 3/4 toxicities exhibited a trend towards higher Cmax, AUC0-∞ and lower CL in the first cycle compared to those who did not have toxicities. Wide interpatient difference in percentage decrease of nadir haemoglobin, absolute neutrophil count and platelet from baseline in cycle was also observed. Individual SNP association tests revealed SNPs each in RXRα [IVS5+288C>T (rs7861779), IVS7+70A>G (rs1536475), IVS8+106A>G (rs35443779), *846G>A (rs4240711) and *+4458G>A (rs3132291)] and HNF4α [-728A>C (rs1800963), IVS6+141A>G (rs6103731), IVS7-88T>C (rs2273618), IVS9+354G>T (rs3818247) and IVS9–145T>C (rs3746574)] to be significantly correlated with altered docetaxel pharmacokinetics Subsequent haplotype association analysis has identified the RXRα LD block ix McCarthy JS, Tannock IF, Degendorfer P, Panzarella T, Furlan M and Siu LL (2002) A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol 38:686690. McKeage MJ (1995) Comparative adverse effect profiles of platinum drugs. Drug Saf 13:228-244. Meier-Abt F, Mokrab Y and Mizuguchi K (2005) Organic anion transporting polypeptides of the OATP/SLCO superfamily: identification of new members in nonmammalian species, comparative modeling and a potential transport mode. J Membr Biol 208:213-227. Meissner K, Jedlitschky G, Meyer zu Schwabedissen H, Dazert P, Eckel L, Vogelgesang S, Warzok RW, Bohm M, Lehmann C, Wendt M, Cascorbi I and Kroemer HK (2004) Modulation of multidrug resistance P-glycoprotein (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics 14:381-385. Mhaidat NM, Thorne RF, de Bock CE, Zhang XD and Hersey P (2008) Melanoma cell sensitivity to Docetaxel-induced apoptosis is determined by class III beta-tubulin levels. FEBS Lett 582:267-272. Miettinen S, Grenman S and Ylikomi T (2009) Inhibition of P-glycoproteinmediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposure. Anti-Cancer Drugs 20:267-276. Mikkaichi T, Suzuki T, Tanemoto M, Ito S and Abe T (2004) The organic anion transporter (OATP) family. Drug Metab Pharmacokinet 19:171179. Miller MC, Johnson KR, Willingham MC and Fan W (1999) Apoptotic cell death induced by baccatin III, a precursor of paclitaxel, may occur without G(2)/M arrest. Cancer Chemother Pharmacol 44:444-452. Miller WL, Agrawal V, Sandee D, Tee MK, Huang N, Choi JH, Morrissey K and Giacomini KM (2011) Consequences of POR mutations and polymorphisms. Mol Cell Endocrinol 336:174-179. Min G, Kemper JK and Kemper B (2002) Glucocorticoid receptor-interacting protein mediates ligand-independent nuclear translocation and activation of constitutive androstane receptor in vivo. J Biol Chem 277:26356-26363. Minami H, Kawada K, Sasaki Y, Igarashi T, Saeki T, Tahara M, Itoh K and Fujii H (2006) Pharmacokinetics and pharmacodynamics of proteinunbound docetaxel in cancer patients. Cancer Sci 97:235-241. 382 Minami H, Kawada K, Sasaki Y, Tahara M, Igarashi T, Itoh K, Fujii H, Saeki T, Ozawa K and Sato H (2009) Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Sci 100:144-149. Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J-i, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A and Saijo N (2007) Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 17:497-504. Mishra PJ, Humeniuk R, Longo-Sorbello GS, Banerjee D and Bertino JR (2007) A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci U S A 104:13513-13518. Mitchison T and Kirschner M (1984) Dynamic instability of microtubule growth. Nature 312:237-242. Moehren U, Eckey M and Baniahmad A (2004) Gene repression by nuclear hormone receptors. Essays Biochem 40:89-104. Moller AM, Urhammer SA and Dalgaard LT (1997) Studies of the genetic variability of the coding region of the hepatocyte nuclear factor-4α in Caucasians with matu-rity onset NIDDM. Diabetologia 40:980-983. Monegier B, Gaillard C, Sable S and Vuilhorgne M (1994) Structures of the major human metabolites of docetaxel (RP 56976 - Taxotere). Tetrahedron Lett 35:3715–3718. Moore LB, Parks DJ, Jones SA, Bledsoe RK, Consler TG, Stimmel JB, Goodwin B, Liddle C, Blanchard SG, Willson TM, Collins JL and Kliewer SA (2000) Orphan Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Share Xenobiotic and Steroid Ligands. J Biol Chem 275:15122-15127. Moore LE, Brennan P, Karami S, Menashe I, Berndt SI, Dong LM, Meisner A, Yeager M, Chanock S, Colt J, Schwartz K, Davis F, Zaridze D, Mattveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Holcatova I, Boffetta P, Chow WH, Rosenberg PS and Rothman N (2009) Apolipoprotein E/C1 locus variants modify renal cell carcinoma risk. Cancer Res 69:8001-8008. Motsinger AA and Ritchie MD (2006) Multifactor dimensionality reduction: an analysis strategy for modelling and detecting gene-gene interactions in human genetics and pharmacogenomics studies. Hum Genomics 2:318-328. 383 Muangmoonchai R, Smirlis D, Wong SC, Edwards M, Phillips IR and Shephard EA (2001) Xenobiotic induction of cytochrome P450 2B1 (CYP2B1) is mediated by the orphan nuclear receptor constitutive androstane receptor (CAR) and requires steroid co-activator (SRC-1) and the transcription factor Sp1. Biochem J 355:71-78. Muller M, Mayer R, Hero U and Keppler D (1994) ATP-dependent transport of amphiphilic cations across the hepatocyte canalicular membrane mediated by mdr1 P-glycoprotein. FEBS Lett 343:168-172. Munro AW, Noble MA, Robledo L, Daff SN and Chapman SK (2001) Determination of the redox properties of human NADPH-cytochrome P450 reductase. Biochemistry 40:1956-1963. Muto M, Onogawa T, Suzuki T, Ishida T, Rikiyama T, Katayose Y, Ohuchi N, Sasano H, Abe T and Unno M (2007) Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. Cancer Sci 98:1570-1576. Naesens M, Kuypers DR, Verbeke K and Vanrenterghem Y (2006) Multidrug resistance protein genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82:10741084. Nakamura K, Moore R, Negishi M and Sueyoshi T (2007) Nuclear pregnane X receptor cross-talk with FoxA2 to mediate drug-induced regulation of lipid metabolism in fasting mouse liver. J Biol Chem 282:9768-9776. Nakhei H, Lingott A, Lemm I and Ryffel GU (1998) An alternative splice variant of the tissue specific transcription factor HNF4alpha predominates in undifferentiated murine cell types. Nucleic Acids Res 26:497-504. Narasaki F, Oka M, Nakano R, Ikeda K, Fukuda M, Nakamura T, Soda H, Nakagawa M, Kuwano M and Kohno S (1997) Human canalicular multispecific organic anion transporter (cMOAT) is expressed in human lung, gastric, and colorectal cancer cells. Biochem Biophys Res Commun 240:606-611. Nebert DW and Russell DW (2002) Clinical importance of the cytochromes P450. Lancet 360:1155-1162. Ngeow J, Lim WT, Leong SS, Ang MK, Toh CK, Gao F, Chowbay B and Tan EH (2011) Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. Ann Oncol 22:718-722. Nishimura M, Naito S and Yokoi T (2004) Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab Pharmacokinet 19:135-149. 384 Oleson L, von Moltke LL, Greenblatt DJ and Court MH (2010) Identification of polymorphisms in the 3'-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism. Xenobiotica 40:146-162. Onoue M, Terada T, Kobayashi M, Katsura T, Matsumoto S, Yanagihara K, Nishimura T, Kanai M, Teramukai S, Shimizu A, Fukushima M and Inui K-i (2009) UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol 14:136-142. Oselin K, Mrozikiewicz PM, Pahkla R and Roots I (2003) Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS-sorted peripheral blood CD4+, CD8+, CD19+, and CD56+ cells. Eur J Haematol 71:119-123. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A and Sarkadi B (2001) Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 285:111-117. Parise RA, Ramanathan RK, Zamboni WC and Egorin MJ (2003) Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. J Chromatogr B Biomed Sci App 783:231-236. Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P and Vilarem MJ (2001) Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Eur J Biochem 268:6346-6357. Pascussi JM, Robert A, Moreau A, Ramos J, Bioulac-Sage P, Navarro F, Blanc P, Assenat E, Maurel P and Vilarem MJ (2007) Differential regulation of constitutive androstane receptor expression by hepatocyte nuclear factor4alpha isoforms. Hepatology (Baltimore, Md) 45:11461153. Picard N, Yee SW, Woillard JB, Lebranchu Y, Le Meur Y, Giacomini KM and Marquet P (2009) The Role of Organic Anion–Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid Pharmacokinetics. Clin Pharmacol Ther 87:100-108. Pitarque M, Rodríguez-Antona C, Oscarson M and Ingelman-Sundberg M (2005) Transcriptional regulation of the human CYP2A6 gene. J Pharmacol Exp Ther 313:814-822. Poon D, Chowbay B, Cheung YB, Leong SS and Tan EH (2005) Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma. Cancer 103:576-581. 385 Pratt WB and Toft DO (1997) Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18:306-360. Purcell S, Daly MJ and Sham PC (2007) WHAP: haplotype-based association analysis. Bioinformatics 23:255-256. Ramamoorthy A, Li L, Gaedigk A, Bradford LD, Benson EA, Flockhart DA and Skaar TC (2012) In silico and in vitro identification of microRNAs that regulate hepatic nuclear factor 4α expression. Drug Metab Dispos 40:726-733. Ramsey LB, Bruun GH, Yang W, Trevino LR, Vattathil S, Scheet P, Cheng C, Rosner GL, Giacomini KM, Fan Y, Sparreboom A, Mikkelsen TS, Corydon TJ, Pui CH, Evans WE and Relling MV (2012) Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Research 22:1-8. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW and Hudes GR (1998) Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77:562-566. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ and Malkowicz SB (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90:1225-1229. Reynolds JA (1979) The role of micelles in protein--detergent interactions. Methods Enzymol 61:58-62. Ringel I and Horwitz SB (1991) Studies with RP 56976 (Taxotere): a semisynthetic analog of Taxol. J Natl Cancer Inst 83:288-291. Riou JF, Naudin A and Lavelle F (1992) Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 187:164-170. Riou JF, Petingenet O, Combeau C and Lavelle F (1994) Cellular uptake and efflux of docetaxel (Taxotere) and paclitaxel (Taxol) in P388 cell line. Proc Am Assoc Cancer Res 35:384. Rodionov VI and Borisy GG (1997) Microtubule treadmilling in vivo. Science 275:215-218. Rosenfeld JM, Vargas R, Jr., Xie W and Evans RM (2003) Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor. Mol Endocrinol 17:1268-1282. Roy JN, Lajoie J, Zijenah LS, Barama A, Poirier C, Ward BJ and Roger M (2005) CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 33:884-887. 386 Royer I, Monsarrat B, Sonnier M, Wright M and Cresteil T (1996) Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 56:58-65. Rudek MA, Sparreboom A, Garrett-Mayer ES, Armstrong DK, Wolff AC, Verweij J and Baker SD (2004) Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer 40:1170-1178. Ruse MD, Privalsky ML and Sladek FM (2002) Competitive Cofactor Recruitment by Orphan Receptor Hepatocyte Nuclear Factor 1: Modulation by the F Domain. Mol Cell Biol 22:1626-1638. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S, Mullikin JC, Mortimore BJ, Willey DL, Hunt SE, Cole CG, Coggill PC, Rice CM, Ning Z, Rogers J, Bentley DR, Kwok PY, Mardis ER, Yeh RT, Schultz B, Cook L, Davenport R, Dante M, Fulton L, Hillier L, Waterston RH, McPherson JD, Gilman B, Schaffner S, Van Etten WJ, Reich D, Higgins J, Daly MJ, Blumenstiel B, Baldwin J, Stange-Thomann N, Zody MC, Linton L, Lander ES and Altshuler D (2001) A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409:928-933. Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H, Hasegawa R, Kaniwa N, Sawada J-i, Komamura K, Ueno K, Kamakura S, Kitakaze M, Kitamura Y, Kamatani N, Minami H, Ohtsu A, Shirao K, Yoshida T and Saijo N (2004) UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecanadministered Japanese patients with cancer. Clin Pharmacol Ther 75:501-515. Sale S, Sung R, Shen P, Yu K, Wang Y, Duran GE, Kim JH, Fojo T, Oefner PJ and Sikic BI (2002) Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol Cancer Ther 1:215-225. Sandanaraj E, Lal S, Selvarajan V, Ooi LL, Wong ZW, Wong NS, Ang PCS, Lee EJD and Chowbay B (2008) PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. Clin Cancer Res 14:7116-7126. Sandusky GE, Mintze KS, Pratt SE and Dantzig AH (2002) Expression of multidrug resistance-associated protein (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 41:65-74. 387 Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL and Gonzalez FJ (2000) CYP3A4 allelic variants with amino acid substitutions in exons and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 67:48-56. Satlin LM, Amin V and Wolkoff AW (1997) Organic anion transporting polypeptide mediates organic anion/HCO3- exchange. J Biol Chem 272:26340-26345. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV and Gottesman MM (2007) Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res 67:9609-9612. Schaid DJ, Rowland CM, Tines DE, Jacobson RM and Poland GA (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70:425-434. Schipani A, Siccardi M, D'Avolio A, Baietto L, Simiele M, Bonora S, Rodriguez Novoa S, Cuenca L, Soriano V, Chierakul N, Saguenwong N, Chuchuttaworn C, Hoskins JM, Dvorak AM, McLeod HL, Davies G, Khoo S, Back DJ, Di Perri G and Owen A (2010) Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother 54:5242-5250. Schwarz UI, Meyer zu Schwabedissen HE, Tirona RG, Suzuki A, Leake BF, Mokrab Y, Mizuguchi K, Ho RH and Kim RB (2011) Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. Pharmacogenet Genomics 21:103-114. Shalli K, Brown I, Heys SD and Schofield AC (2005) Alterations of betatubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J 19:1299-1301. Sharom FJ (2008) ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9:105-127. Sheskin David J (2004) Handbook of Parametric and Nonparametric Statistical Procedures. Routledge. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423. Shiraki T, Sakai N, Kanaya E and Jingami H (2003) Activation of orphan nuclear constitutive androstane receptor requires subnuclear targeting 388 by peroxisome proliferator-activated receptor gamma coactivator-1 alpha. A possible link between xenobiotic response and nutritional state. J Biol Chem 278:11344-11350. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ and Gelboin HV (1998) Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8:391-401. Sidhu JS and Omiecinski CJ (1997) An okadaic acid-sensitive pathway involved in the phenobarbital-mediated induction of CYP2B gene expression in primary rat hepatocyte cultures. J Pharmacol Exp Ther 282:1122-1129. Sim SC, Kacevska M and Ingelman-Sundberg M (2013) Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J 13:1-11. Sims-Mourtada J, Izzo JG, Ajani J and Chao KS (2007) Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 26:5674-5679. Singh RR, Kunkalla K, Qu C, Schlette E, Neelapu SS, Samaniego F and Vega F (2011) ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 30:4874-4886. Sissung TM, Baum CE, Deeken J, Price DK, Ching J, Steinberg SM, Dahut W, Sparreboom A, Figg and Wd (2008) ABCB1GeneticVariation Influences theToxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel. Clin Cancer Res 14:4543-4549. Sladek FM, Zhong WM, Lai E and Darnell JE (1990) Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. Genes Dev 4:2353-2365. Smith NF, Acharya MR, Desai N, Figg WD and Sparreboom A (2005) Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 4:815-818. Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, Figg WD, Verweij J, McLeod HL and Sparreboom A (2007) Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 81:76-82. Song P, Lamba JK, Zhang L, Schuetz E, Shukla N, Meibohm B and Yates CR (2006) G2677T and C3435T genotype and haplotype are associated 389 with hepatic ABCB1 (MDR1) expression. J Clin Pharmacol 46:373379. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij J and McLeod HL (2004) Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 76:38-44. Sparreboom A, Van Tellingen O, Scherrenburg EJ, Boesen JJ, Huizing MT, Nooijen WJ, Versluis C and Beijnen JH (1996) Isolation, purification and biological activity of major docetaxel metabolites from human feces. Drug Metab Dispos 24:655-658. Squires EJ, Sueyoshi T and Negishi M (2004) Cytoplasmic localization of pregnane X receptor and ligand-dependent nuclear translocation in mouse liver. J Biol Chem 279:49307-49314. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH and Kliewer SA (2001) The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A 98:3369-3374. Stengel C, Newman SP, Leese MP, Potter BVL, Reed MJ and Purohit A (2009) Class III [beta]-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer 102:316-324. Stoffel M and Duncan SA (1997) The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. Proc Natl Acad Sci U S A 94:13209-13214. Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P and Negishi M (1999) The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 274:6043-6046. Sueyoshi T and Negishi M (2001) Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu Rev Pharmacol Toxicol 41:123-143. Sugatani J, Kojima H, Ueda A, Kakizaki S, Yoshinari K, Gong QH, Owens IS, Negishi M and Sueyoshi T (2001) The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. Hepatology 33:1232-1238. Sugatani J, Sueyoshi T, Negishi M and Miwa M (2005) Regulation of the human UGT1A1 gene by nuclear receptors constitutive 390 active/androstane receptor, pregnane X receptor, and glucocorticoid receptor. Methods Enzymol 400:92-104. Suino K, Peng L, Reynolds R, Li Y, Cha J-Y, Repa JJ, Kliewer SA and Xu HE (2004) The nuclear xenobiotic receptor CAR: structural determinants of constitutive activation and heterodimerization. Mol Cell 16:893-905. Swales K and Negishi M (2004) CAR, driving into the future. Mol Endocrinol 18:1589-1598. Swart M, Whitehorn H, Ren Y, Smith P, Ramesar RS and Dandara C (2012) PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients. BMC Med Genet 13:112. Synold TW, Dussault I and Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584-590. Taamma A, Fandi A, Azli N, Wibault P, Chouaki N, Hasbini A, Couteau C, Armand JP and Cvitkovic E (1999) Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer 86:1101-1108. Takagi S, Nakajima M, Mohri T and Yokoi T (2008) Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 283:9674-9680. Tan EH, Khoo KS, Wee J, Fong KW, Lee KS, Lee KM, Chua ET, Tan T, Khoo-Tan HS, Yang TL, Au E, Tao M, Ong YK and Chua EJ (1999) Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 10:235237. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I and Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84:7735-7738. Thomas H, Jaschkowitz K, Bulman M, Frayling TM, Mitchell SM, Roosen S, Lingott-Frieg A, Tack CJ, Ellard S, Ryffel GU and Hattersley AT (2001) A distant upstream promoter of the HNF-4alpha gene connects the transcription factors involved in maturity-onset diabetes of the young. Hum Mol Genet 10:2089-2097. Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA and Di Rienzo A (2004) CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 75:1059-1069. 391 Thorn M, Finnstrom N, Lundgren S, Rane A and Loof L (2005) Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 60:54-60. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, Marsh CL, McVicar JP, Barr DM, Perkins JD and et al. (1994) Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 271:557566. Tirona RG, Lee W, Leake BF, Lan L-B, Cline CB, Lamba V, Parviz F, Duncan SA, Inoue Y, Gonzalez FJ, Schuetz EG and Kim RB (2003) The orphan nuclear receptor HNF4alpha determines PXR- and CARmediated xenobiotic induction of CYP3A4. Nat Med 9:220-224. Toh S, Wada M, Uchiumi T, Inokuchi A, Makino Y, Horie Y, Adachi Y, Sakisaka S and Kuwano M (1999) Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet 64:739-746. Tompkins LM, Sit TL and Wallace AD (2008) Unique transcription start sites and distinct promoter regions differentiate the pregnane X receptor (PXR) isoforms PXR and PXR 2. Drug Metab Dispos 36:923-929. Torres-Padilla ME, Fougère-Deschatrette C and Weiss MC (2001) Expression of HNF4alpha isoforms in mouse liver development is regulated by sequential promoter usage and constitutive 3' end splicing. Mech Dev 109:183-193. Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, Dieras V, Pons G, Goldwasser F and Tréluyer JM (2006) Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 79:570-580. Trock BJ, Leonessa F and Clarke R (1997) Multidrug Resistance in Breast Cancer: a Meta-analysis of MDR1/gp170 Expression and Its Possible Functional Significance. J Natl Cancer Inst 89:917-931. Tsujimoto M, Dan Y, Hirata S, Ohtani H and Sawada Y (2008) Influence of SLCO1B3 gene polymorphism on the pharmacokinetics of digoxin in terminal renal failure. Drug Metab Pharmacokinet 23:406-411. Tsujimoto M, Hirata S, Dan Y, Ohtani H and Sawada Y (2006) Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects. Drug Metab Pharmacokinet 21:165-169. 392 Urano N, Fujiwara Y, Doki Y, Kim SJ, Miyoshi Y, Noguchi S, Miyata H, Takiguchi S, Yasuda T, Yano M and Monden M (2006) Clinical significance of class III β-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol 28:375-381. Urano T, Usui T, Shiraki M, Ouchi Y and Inoue S (2009) Association of a single nucleotide polymorphism in the constitutive androstane receptor gene with bone mineral density. Geriatr Gerontol Int 9:235-241. Urien S, Barre J, Morin C, Paccaly A, Montay G and Tillement JP (1996) Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest New Drugs 14:147-151. Urquhart BL, Tirona RG and Kim RB (2007) Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol 47:566-578. Vaclavikova R, Soucek P, Svobodova L, Anzenbacher P, Simek P, Guengerich FP and Gut I (2004) Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs. Drug Metab Dispos 32:666-674. Van de Steeg E, van Esch A, Wagenaar E, van der Kruijssen CMM, van Tellingen O, Kenworthy KE and Schinkel AH (2011) High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin Cancer Res 17:294-301. van Tellingen O, Beijnen JH, Verweij J, Scherrenburg EJ, Nooijen WJ and Sparreboom A (1999) Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin Cancer Res 5:2918-2924. van Waterschoot RAB, Lagas JS, Wagenaar E, Rosing H, Beijnen JH and Schinkel AH (2010) Individual and combined roles of CYP3A, pglycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. Int J Cancer. van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G and Sparreboom A (2000) Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 6:2598-2603. Vilmar AC, Santoni-Rugiu E and Sorensen JB (2011) Class III beta-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial. Clin Cancer Res 17:5205-5214. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M and Armstrong VW (2001) No influence of the MDR-1 C3435T polymorphism or a 393 CYP3A4 promoter polymorphism (CYP3A4-V allele) on doseadjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 47:1048-1052. Wada M, Toh S, Taniguchi K, Nakamura T, Uchiumi T, Kohno K, Yoshida I, Kimura A, Sakisaka S, Adachi Y and Kuwano M (1998) Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/DubinJohnson syndrome. Hum Mol Genet 7:203-207. Wagner-Souza K, Diamond HR, Ornellas MH, Gomes BE, Almeida-Oliveira A, Abdelhay E, Bouzas LF and Rumjanek VM (2008) Rhodamine 123 efflux in human subpopulations of hematopoietic stem cells: Comparison between bone marrow, umbilical cord blood and mobilized peripheral blood CD34+ cells. Int J Mol Med 22:237-242. Wan YJ, An D, Cai Y, Repa JJ, Hung-Po Chen T, Flores M, Postic C, Magnuson MA, Chen J, Chien KR, French S, Mangelsdorf DJ and Sucov HM (2000) Hepatocyte-specific mutation establishes retinoid X receptor alpha as a heterodimeric integrator of multiple physiological processes in the liver. Mol Cell Biol 20:4436-4444. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ and Wilkinson GR (2000) CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'promoter region polymorphism. Clin Pharmacol Ther 68:82-91. Wang D, Guo Y, Wrighton SA, Cooke GE and Sadee W (2010) Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. Wang D, Johnson AD, Papp AC, Kroetz DL and Sadée W (2005) Multidrug resistance polypeptide (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15:693-704. Wang TL and Tan YO (1991) Cisplatin and 5-fluorouracil continuous infusion for metastatic nasopharyngeal carcinoma. Ann Acad Med Singapore 20:601-603. Wani MC, Taylor HL, Wall ME, Coggon P and McPhail AT (1971) Plant antitumour agents VI: The isolation and structure of taxol, a novel antileukemic and antitumour agent from Taxus brevfolia. J Am Chem Soc 93:2325-2327. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, Chua ET, Yang E, Lee KM, Fong KW, Tan HS, Lee KS, Loong S, Sethi V, Chua EJ and Machin D (2005) Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against 394 cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23:6730-6738. Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, IngelmanSundberg M and Oscarson M (2001) Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 281:1349-1355. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR and Ingelman-Sundberg M (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755-761. Wilkinson GR (1996) Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 24:475-490. Willson TM and Kliewer SA (2002) Pxr, car and drug metabolism. Nat Rev Drug Discov 1:259-266. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ and Scherman D (1994) Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol 48:1528-1530. Wirsing A, Senkel S, Klein-Hitpass L, Ryffel GU and Tian B (2011) A systematic analysis of the 3'UTR of HNF4A mRNA reveals an interplay of regulatory elements including miRNA target sites. PLoS One 6:e27438. Wisely GB, Miller AB, Davis RG, Thornquest AD, Johnson R, Spitzer T, Sefler A, Shearer B, Moore JT, Miller AB, Willson TM and Williams SP (2002) Hepatocyte nuclear factor is a transcription factor that constitutively binds fatty acids. Structure 10:1225-1234. Wortham M, Czerwinski M, He L, Parkinson A and Wan Y-JY (2007) Expression of constitutive androstane receptor, hepatic nuclear factor alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab Dispos 35:1700-1710. Xie W, Barwick JL, Downes M, Blumberg B, Simon CM, Nelson MC, Neuschwander-Tetri BA, Brunt EM, Guzelian PS and Evans RM (2000) Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406:435-439. Xu C, Li CYT and Kong ANT (2005) Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 28:249-268. 395 Xu Z, Kaplan NL and Taylor JA (2007) TAGster: efficient selection of LD tag SNPs in single or multiple populations. Bioinformatics 23:3254-3255. Yamakawa Y, Hamada A, Nakashima R, Yuki M, Hirayama C, Kawaguchi T and Saito H (2011) Association of Genetic Polymorphisms in the Influx Transporter SLCO1B3 and the Efflux Transporter ABCB1 With Imatinib Pharmacokinetics in Patients With Chronic Myeloid Leukemia. Ther Drug Monit 33:244-250. Yamamoto N, Tamura T, Murakami H, Shimoyama T, Nokihara H, Ueda Y, Sekine I, Kunitoh H, Ohe Y, Kodama T, Shimizu M, Nishio K, Ishizuka N and Saijo N (2005) Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol 23:1061-1069. Yeo W, Leung TW, Chan AT, Chiu SK, Yu P, Mok TS and Johnson PJ (1998) A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer 34:2027-2031. Yoshinari K, Yoda N, Toriyabe T and Yamazoe Y (2010) Constitutive androstane receptor transcriptionally activates human CYP1A1 and CYP1A2 genes through a common regulatory element in the 5'flanking region. Biochem Pharmacol 79:261-269. Yuan HY, Chiou JJ, Tseng WH, Liu CH, Liu CK, Lin YJ, Wang HH, Yao A, Chen YT and Hsu CN (2006) FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res 34:W635-W641. Yvon AM, Wadsworth P and Jordan MA (1999) Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 10:947-959. Zeigler-Johnson C, Friebel T, Walker AH, Wang Y, Spangler E, Panossian S, Patacsil M, Aplenc R, Wein AJ, Malkowicz SB and Rebbeck TR (2004) CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res 64:8461-8467. Zhai Y, Pai HV, Zhou J, Amico JA, Vollmer RR and Xie W (2007) Activation of pregnane X receptor disrupts glucocorticoid and mineralocorticoid homeostasis. Mol Endocrinol 21:138-147. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Wrighton SA, Hancock M, Kim RB, Strom S, Thummel K, Russell CG, Hudson JR, Schuetz EG and Boguski MS (2001) The human pregnane X receptor: genomic 396 structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11:555-572. Zhang X, Li L, Ding X and Kaminsky LS (2011) Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. Drug Metab Dispos 39:1433-1439. Zhang Z, Burch PE, Cooney AJ, Lanz RB, Pereira FA, Wu J, Gibbs RA, Weinstock G and Wheeler DA (2004) Genomic analysis of the nuclear receptor family: new insights into structure, regulation, and evolution from the rat genome. Genome Res 14:580-590. Zhao Y, Song M, Guan D, Bi S, Meng J, Li Q and Wang W (2005) Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant Proc 37:178-181. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, Boyle G, Law Y, Miller S, Lamba J and Burckart GJ (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3:477-483. Zhou L-P, Yao F, Luan H, Wang Y-L, Dong X-H, Zhou W-W and Wang Q-H (2012) CYP3A4*1B polymorphism and cancer risk: A HuGE review and meta-analysis. Tumor Biol:1-12. Zhou SF, Di YM, Chan E, Du YM, Chow VD, Xue CC, Lai X, Wang JC, Li CG, Tian M and Duan W (2008) Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 9:738-784. Zhu Q, Yamagata K, Miura A, Shihara N, Horikawa Y, Takeda J, Miyagawa J and Matsuzawa Y (2003) T130I mutation in HNF-4alpha gene is a loss-of-function mutation in hepatocytes and is associated with lateonset Type diabetes mellitus in Japanese subjects. Diabetologia 46:567-573. Ziebarth JD, Bhattacharya A, Chen A and Cui Y (2012) PolymiRTS Database 2.0: linking polymorphisms in microRNA target sites with human diseases and complex traits. Nucleic Acids Res 40:D216-221. 397 [...]... 2001) In light of the central role of PXR in drug disposition and its broad ligand / substrate specificity, functional genetic polymorphisms in the gene encoding PXR may have pronounced impact on drug pharmacokinetics Therefore, the exploration of the pharmacogenetics influences of PXR may provide insight on the interindividual variability in the disposition of PXR ligands substrates 1.1.1.1 Pharmacogenetics. .. results in the formation of haplotype blocks that consist of the particular combination of alleles (Gabriel, 2002) The tendency of a genetic variant in causing functional effects depends on its type and location Firstly, variants in the promoter region can affect the transcriptional activity of the gene, resulting in altered level of gene expression Secondly, genetic alterations in the coding region of a... each) and Chinese nasopharyngeal cancer patients (N = 50) In- silico functional predictions of RXRα polymorphisms RXRα SNPs and their relationships with pharmacokinetics and pharmacodynamics of docetaxel in Chinese nasopharyngeal cancer patients (N = 50) RXRα LD block haplotypes and diplotypes in Chinese nasopharyngeal cancer patients (N = 50) Influence of RXRα haplotypes on docetaxel pharmacokinetics. .. DESCRIPTION Demographic and clinical characteristics of Chinese nasopharyngeal cancer patients (N = 50) Summary of docetaxel pharmacokinetics in Chinese nasopharyngeal cancer patients (N = 50) Summary of percentage decrease of nadir blood count from baseline in cycle 1 in Chinese nasopharyngeal cancer patients (N = 50) Summary of the incidence of grade 3 & 4 docetaxel toxicity in Asian nasopharyngeal cancer. .. deletion of 37 amino acids in the ligand-binding domain The lack of ligand binding ability might be responsible for the failure of this transcript in transactivating the target genes (Gardner-Stephen et al., 2004) PXR is ubiquitously expressed in the xenobiotics detoxification organs, such as liver, intestine and kidney While the DNA binding domain is highly conserved at 96% similarity, the ligand binding... DESCRIPTION In- silico functional predictions of HNF4α polymorphisms HNF4α SNPs and their relationships with pharmacokinetics and pharmacodynamics of docetaxel in Chinese nasopharyngeal cancer patients (N = 50) HNF4α LD block haplotypes and diplotypes in Chinese nasopharyngeal cancer patients (N = 50) Influence of HNF4α haplotypes on docetaxel pharmacokinetics Genotype and allelic frequencies of CYP3A4 and. .. metabolism and excretion of a drug molecule and its metabolites Pharmacodynamics, on the other hand, is a study on the biochemical and physiological effects of a drug molecule and its metabolites The perturbations in these parameters are the consequences of polygenic traits Alterations in the expression or function of drug metabolism enzymes, drug transporters or drug targets due to the presence of cis-acting... 2001) These receptors remain in this category despite the subsequent characterisation of specific ligands Typically, nuclear receptors have three main functional domains: an amino terminal domain that contains activation function 1 (AF-1), a highly conserved DNA binding domain (DBD), and a carboxyl terminal ligand binding domain (LBD) that contains dimerisation motif and ligand-dependent transcriptional... due to the altered local efflux of the docetaxel in blood cells in the presence of variants Our data showed that several SNPs and haplotypes in the genes along the biochemical pathway of docetaxel might contribute to the interindividual variability in the pharmacokinetics and pharmacodynamics of docetaxel Apart from pharmacogenetics, environmental factors and clinical characteristics are among the plausible... involved in the metabolism of a broad range of clinical drugs Thus, the administration of PXR ligands can lead to accelerated drug clearance and drug-drug interaction This is of clinical importance in view of the promiscuous nature of PXR in binding ligands, and its extensive regulatory effects on majority of the disposition genes PXR modulates the expressions of a wide range of disposition genes To . DOCETAXEL PHARMACOGENETICS AND ITS INFLUENCE ON THE PHARMACOKINETICS / PHARMACODYNAMICS OF DOCETAXEL IN ASIAN NASOPHARYNGEAL CANCER PATIENTS Chew Sin Chi B. Health Sciences (Hons),. and Chowbay B. 3. American Society of Clinical Oncology (ASCO), USA 2012. Docetaxel pharmacogenetics: The influence of RXRα and HNF4α genetic variations on docetaxel disposition in Asian nasopharyngeal. polymorphisms and their relationships with pharmacokinetics and pharmacodynamics of docetaxel in Chinese nasopharyngeal cancer patients (N = 50). 30 9 Table 3.26 Influence of SLCO1B3 haplotype constructs